Authors: Eli Y Adashi, Rajiv C McCoy
Summary:
Assisted reproductive technologies (ART) have become the standard of care for the treatment of infertility. Within this realm, reliable prediction of the developmental potential of the pre‐implantation human embryo remains an overriding priority. One such technology, pre‐implantation genetic screening (PGS), is being increasingly deployed to select against embryonic aneuploidy [1]. However, a growing number of seemingly contradictory outcome reports are forcing a reevaluation of this approach. Here, we discuss how biological factors, notably mitotic aneuploidy during early embryonic development, limit the very rationale for PGS as a clinical diagnostic method.
Source:
EMBO Reports; 2017, e201743941